These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 1384436)

  • 1. [Recent advances in ovarian cancer chemotherapy].
    Hatae M; Onishi Y; Kume H; Maeda Y; Nakagawa S; Hokanishi H
    Gan To Kagaku Ryoho; 1992 Oct; 19(12):1982-90. PubMed ID: 1384436
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A systematic overview of chemotherapy effects in ovarian cancer.
    Högberg T; Glimelius B; Nygren P;
    Acta Oncol; 2001; 40(2-3):340-60. PubMed ID: 11441940
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future directions in the chemotherapy of ovarian cancer.
    Ozols RF
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-86-S15-90. PubMed ID: 9346230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carboplatin versus cisplatin in ovarian cancer.
    Alberts DS
    Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of advanced ovarian cancer.
    Martoni A; Cacciari N; Angelelli B; Zamagni C; Pannuti F
    Front Biosci; 1997 Mar; 2():g20-6. PubMed ID: 9159262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical therapy of advanced malignant epithelial tumours of the ovary.
    Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
    Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Importance of multiagent chemotherapy regimens in ovarian carcinoma: dose intensity analysis.
    Levin L; Simon R; Hryniuk W
    J Natl Cancer Inst; 1993 Nov; 85(21):1732-42. PubMed ID: 8411257
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination regimens of paclitaxel and the platinum drugs as first-line regimens for ovarian cancer.
    Ozols RF
    Semin Oncol; 1995 Dec; 22(6 Suppl 15):1-6. PubMed ID: 8643963
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I trial of carboplatin, paclitaxel, etoposide, and cyclophosphamide with granulocyte colony stimulating factor as first-line therapy for patients with advanced epithelial ovarian cancer.
    Tung N; Berkowitz R; Matulonis U; Quartulli M; Seiden M; Kim Y; Niloff J; Cannistra SA
    Gynecol Oncol; 2000 May; 77(2):271-7. PubMed ID: 10785477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
    Harper P
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial.
    International Collaborative Ovarian Neoplasm Group
    Lancet; 2002 Aug; 360(9332):505-15. PubMed ID: 12241653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial with pharmacokinetic analyses of high-dose carboplatin, etoposide, and cyclophosphamide with autologous bone marrow transplantation in patients with refractory germ cell tumors.
    Motzer RJ; Gulati SC; Tong WP; Menendez-Botet C; Lyn P; Mazumdar M; Vlamis V; Lin S; Bosl GJ
    Cancer Res; 1993 Aug; 53(16):3730-5. PubMed ID: 8393380
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ovarian cancer, Part II: Treatment.
    Ozols RF
    Curr Probl Cancer; 1992; 16(2):61-126. PubMed ID: 1617996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The integration of paclitaxel and new platinum compounds in the treatment of advanced ovarian cancer.
    Vermorken JB
    Int J Gynecol Cancer; 2001; 11 Suppl 1():21-30. PubMed ID: 11488999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carboplatin/paclitaxel versus cisplatin/paclitaxel as first-line chemotherapy in advanced ovarian cancer: an interim analysis of a randomized phase III trial of the Arbeitsgemeinschaft Gynäkologische Onkologie Ovarian Cancer Study Group.
    du Bois A; Lück HJ; Meier W; Möbus V; Costa S; Richter B; Warm M; Bauknecht T; Schröder W; Olbricht S; Nitz U; Jackisch C
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-44-S15-52. PubMed ID: 9346222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of advanced ovarian cancer.
    McGuire WP; Ozols RF
    Semin Oncol; 1998 Jun; 25(3):340-8. PubMed ID: 9633846
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of chemotherapy in the future treatment of ovarian cancer.
    Ozols RF
    Acta Obstet Gynecol Scand Suppl; 1992; 155():55-60. PubMed ID: 1354405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemotherapy of germ-cell ovarian tumours: first-line treatment with etoposide, bleomycin and cisplatin or carboplatin.
    Smales E; Peckham MJ
    Eur J Cancer Clin Oncol; 1987 May; 23(5):469-74. PubMed ID: 2443358
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is paclitaxel/carboplatin really a useful regimen for ovarian cancer compared with platinum/doxorubicin/cyclophosphamide?
    Sugiyama T
    Int J Clin Oncol; 2006 Jun; 11(3):163. PubMed ID: 16850120
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.